Related Experiment Videos
Coagulation studies in very low-birthweight infants
1Kansas University Children's Center, Department of Pediatrics, University of Kansas Medical Center, Kansas City.
American Journal of Perinatology
|January 1, 1994
Summary
Establishing reference ranges for coagulation studies in premature infants (24-29 weeks gestational age) is crucial for managing bleeding disorders. This study provides vital prothrombin time, activated partial thromboplastin time, and fibrinogen data for very low-birthweight infants.
Area of Science:
- Neonatal Medicine
- Pediatric Hematology
- Clinical Pathology
Background:
- Premature infants, especially those with very low birth weight, often experience hemostatic disorders.
- Accurate reference values for coagulation parameters in this population are essential for effective clinical management.
- Existing reference ranges may not adequately represent the unique physiological state of extremely premature neonates.
Purpose of the Study:
- To determine reference values for prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen levels in premature infants.
- To establish normal coagulation ranges for infants born between 24 and 29 weeks' gestational age.
- To facilitate comparison with adult reference ranges by converting infant values to ratios.
Main Methods:
- Prospective data collection over a 4-year period from very low-birthweight infants admitted to a neonatal intensive care nursery.
- Measurement of prothrombin time, activated partial thromboplastin time, and plasma fibrinogen levels.
- Calculation of ratios of infant coagulation values to adult control values.
Main Results:
- Fifty-two premature infants (24-29 weeks gestational age) were analyzed.
- Mean PT was 14.5 seconds, mean aPTT was 69.5 seconds, and mean fibrinogen level was 1.35 g/L.
- Ratio comparisons aided in standardizing results against established adult reference ranges.
Conclusions:
- The study provides essential reference values for coagulation parameters in extremely premature infants.
- These data are critical for the diagnosis and management of hemostatic disorders in this vulnerable patient group.
- Normal ranges are needed for developing evidence-based protocols to prevent complications of abnormal coagulation in preterm neonates.